Temodal Capsule All-Case-Registered Surveillance (Designated Drug Use Investigation) - Evaluation of The Safety and Efficacy of Temodal in Patients With Newly Diagnosed Malignant Glioma (Concomitant With Radiotherapy and Then as Monotherapy) and Relapsed Malignant Glioma (as Monotherapy)

Trial Profile

Temodal Capsule All-Case-Registered Surveillance (Designated Drug Use Investigation) - Evaluation of The Safety and Efficacy of Temodal in Patients With Newly Diagnosed Malignant Glioma (Concomitant With Radiotherapy and Then as Monotherapy) and Relapsed Malignant Glioma (as Monotherapy)

Completed
Phase of Trial: Phase IV

Latest Information Update: 17 Nov 2016

At a glance

  • Drugs Temozolomide (Primary)
  • Indications Astrocytoma; Glioma
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Merck & Co
  • Most Recent Events

    • 11 Nov 2016 Status changed from active, no longer recruiting to completed.
    • 16 Mar 2015 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record.
    • 24 Oct 2012 Planned end date changed from 1 Jul 2016 to 1 Oct 2016 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top